System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Julien Edeline is an expert in Oncology at Centre Eugène Marquis (France). As of October 2026, ScienceLeadR ranks Julien Edeline in the top 1% of experts worldwide for Biliary Tract Neoplasms, Liver Neoplasms and Carcinoma. Julien Edeline has authored 336 publications, the most recent in 2026, and is an investigator in 54 clinical trials, 21 of them ongoing. SLR score: 2,256 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Julien Edeline Centre Eugène Marquis France
2 256 ScienceLeadR Reputation 2256

Unlock

Register Login
Network Map

Oncology

Subspecialties: Hepatology - Gastroenterology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2008 - 2026
Source: PubMed

University of Rennes

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 336

Citations

Citations: 18 435 1st author: 48 Last author: 50 Unique author: 2

Main journals

J Clin Oncol 42
Ann Oncol 30
J Hepatol 13
Liver Int 13
Bull Cancer 12

Best Journals

J Clin Oncol 32
Ann Oncol 22
J Hepatol 8

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: longer-term follow-up from the randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-966 trial.
PMID 42898854 — biliary tract neoplasms, safety, neoplasms, biliary tract, therapeutics		EClinicalMedicine20260
EGFR Targeting With Afatinib and Cetuximab Versus Cetuximab Alone in Chemorefractory Wild-type RAS Metastatic Colorectal Cancer: A Randomized Phase II Study With Circulating Tumor Cell Analysis.
PMID 42859101 — cells, cetuximab, neoplastic cells, circulating, neoplasms, afatinib, colorectal neoplasms		Clin Colorectal Cancer20260
Systemic treatment paradigms for unresectable and advanced hepatocellular carcinoma in Europe.
PMID 42819747 — carcinoma, hepatocellular, biomarkers, therapeutics		Lancet Reg Health Eur20261
An integrated Phase II/III randomized study comparing durvalumab and tremelimumab ± Hepatic ArteriaL infusion chemotherapy with GEMOX in hepatocellular Carcinoma with high tumor burdEn - ALICE (PRODIGE89 - UCGI44 - ALICE).
PMID 42736101 — carcinoma, hepatocellular, safety, neoplasms, drug therapy, tumor burden, chemotherapy		Dig Liver Dis20260
Integrating systemic therapy in the earlier stages of liver cancer.
PMID 42744525 — liver diseases, biliary tract neoplasms, carcinoma, hepatocellular, neoplasms, liver, immunotherapy, liver neoplasms, neoadjuvant therapy, therapeutics		J Hepatol Top journal20261

Clinical Studies 54

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 8

By phase:

Phase 3 17
Phase 2 13
N/A 10
Phase 1/Phase 2 6
Phase 2/Phase 3 5
Phase 1 3

By status:

Completed 27
Recruiting 15
Active not recruiting 3
Not yet recruiting 3
Terminated 3
Unknown 3

By type:

Interventional 50
Observational 4

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 4
multicentric5to9 5
multicentricup10 41

Main Topics

Ongoing Clinical Trials

21 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Phase 3 study of RMC 6236 in patients with previously treated metastatic PDAC
2024-516063-89-00 — adenocarcinoma, therapeutics		Phase 3Active not recruiting2025
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy Based Treatment Combinations in Patients with Advanced Liver Cancers (Morpheus Liver)
2023-506611-17-00 — safety, neoplasms, liver, immunotherapy, liver neoplasms, therapeutics		Phase 1/Phase 2Recruiting2026
Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer
NCT07745296 — biliary tract neoplasms, pharmaceutical preparations, neoplasms, biliary tract, precision medicine, therapeutics, capecitabine, cholangiocarcinoma		Phase 3Not yet recruiting2027
TACTIC MP0317 A TUMOR TARGETING FAP DEPENDENT CD40 AGONIST DARPIN IN COMBINATION WITH CHEMOIMMUNOTHERAPY IN FIRST LINE TREATMENT FOR PATIENTS WITH ADVANCED BILIARY TRACT CARCINOMA A RANDOMIZED NON COMPARATIVE PROOF OF CONCEPT PHASE II STUDY
2024-520029-35-01 — neoplasms, maintenance, biliary tract, therapeutics, carcinoma		Phase 2Recruiting2025
PRODIGE 88 CIRCULATE PAC Phase III multicentric open label randomized study to investigate the efficacy of chemotherapy in patients with positive ctDNA after surgery and adjuvant chemotherapy for a high risk stage II and stage III Colorectal Cancer
2023-505046-26-00 — neoplasms, colon, drug therapy, chemotherapy, adjuvant, colorectal neoplasms, chemotherapy, carcinoma		Phase 3Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS